Abbott Laboratories (ABT: Quote) announced that it has received U.S. Food and Drug Administration clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System.
The company said that the system included a touch-screen interface, automated logbook. The system also offers Personalization features, including the ability to upload weekly messages, pre-and post-meal markers and a personal photograph to the home screen.
This unique device is also equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers.
The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months, the company said.
Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org